In this article, we will dive into Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.
The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant changes. The industry, which is thought to account for more than 10% of the world’s GDP, is set to enter a new era characterized by demographic shifts, digital innovation, and regulatory realignment. Stakeholders in the life sciences, diagnostics, and healthcare services ecosystem face a conundrum as of 2025: stability is threatened by ongoing financial strain, growing operational complexity, and geopolitical risks, despite the abundance of growth opportunities.
Healthcare earnings in the U.S. are still under pressure. EBITDA as a percentage of national health spending has dropped by 150 basis points since 2019, which has a significant impact on both payers and providers, according to McKinsey. The World Health Organization projects that there will be a 10-million-person shortage of healthcare workers worldwide by 2030, limited reimbursement growth, and high inflationary prices. At the same time, digital transformation has gained importance. According to Deloitte, 90% of executives in global health systems anticipate a faster adoption of digital technology, and over 70% of them intend to increase operational efficiency in 2025.
Artificial intelligence (AI) is at the heart of this change. AI, which was once aspirational, is now a disruptive force that improves everything from medical diagnosis to hospital logistics. AI is seen by EU institutions as essential to the modernization of public health. The European Health Data Space (EHDS), which will be launched in 2025, and the European Commission’s 2024 AI Act aim to guarantee that AI technologies are reliable and safe, while facilitating access to high-quality, interoperable health data. These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed AI systems, in conjunction with the revised Product Liability Directive.
However, issues remain. Integrating AI into clinical operations necessitates consistent funding, cultural acceptance, and regulatory clarity. Bias in data, ethical considerations, and the complexity of agentic AI solutions—tools that work autonomously to perform multi-step healthcare processes—require careful management. Despite these challenges, practical applications are gaining traction: AI is currently used in early sepsis identification, breast cancer screening, and pharmaceutical R&D, with the potential to shorten medication development timelines and improve patient outcomes.
Meanwhile, recent geopolitical developments are casting a shadow on global healthcare supply networks. In April 2025, President Donald Trump announced substantial tariffs, including a 10% baseline and targeted taxes on medical devices, which might disrupt access to vital inputs like diagnostic tools and protective equipment. “What Trump unveiled Wednesday is stupid, wrong, arrogantly extreme, and ignorant trade-wise,” said billionaire investor Ken Fisher in a harsh indictment of the proposal. Furthermore, Morningstar and Fitch analysts warn of rising expenses for hospitals, which are already dealing with low margins and restricted pricing options.
These changes—technological, legislative, and geopolitical—occur against a backdrop of cautious optimism. While GDP growth in the United States is predicted to drop from 2.7% in 2024 to 1.5% in 2025, the healthcare industry remains strong. As AI integration deepens, policy clarity emerges, and investment cycles reset, the industry may be poised for a new era of growth.
With that context in mind, let’s look at the top ten healthcare stocks in Ken Fisher’s portfolio that have massive upside potential.
Methodology
To create our list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential, we looked at Ken Fisher’s Q4 2024 13F SEC filings to find healthcare stocks in his portfolio. We then chose the ten stocks with the highest upside potential based on average analyst price forecasts, as of the time of writing this article. The equities were then sorted in ascending order of predicted upside. This strategy highlights the most promising healthcare investments in Fisher’s existing portfolio. Furthermore, hedge fund sentiment was also laid out for these stocks, as of Insider Monkey’s Q4 2024 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Stryker Corporation (NYSE:SYK)
Upside Potential: 24.22%
Number of Hedge Fund Holders: 70
Stryker Corporation (NYSE:SYK) is a global medical technology corporation with two major business segments: MedSurg & Neurotechnology and Orthopedics. The company sells surgical equipment, endoscopic systems, neurovascular devices, orthopedic implants, and patient care technologies in approximately 75 countries.
Stryker Corporation (NYSE:SYK) reported strong financial performance for the fourth quarter and full fiscal year ended December 31, 2024. The company recorded 10.2% organic revenue growth for both the quarter and the entire year. Organic sales in the United States increased by 10.6%, while overseas organic sales increased by 8.8%, driven by strong procedural volumes and capital product demand. Adjusted earnings per share for 2024 were $12.19 per share, a 15% increase over 2023, demonstrating the company’s capacity to maintain profit growth despite global economic difficulties.
Stryker Corporation (NYSE:SYK) made a significant move on February 19, 2025, as it acquired Inari Medical, Inc. for $80 per share in cash. Stryker’s acquisition not only increased its foothold in the high-growth venous thromboembolism (VTE) market but also added Inari’s mechanical thrombectomy solutions, the FlowTriever and ClotTriever Systems, to its portfolio. These devices are consistent with Stryker’s aim of providing novel and clinically effective treatments for vascular diseases.
Stryker Corporation (NYSE:SYK) intends to develop its Neurovascular division by using Inari’s expertise in new treatment areas such as chronic venous disease and acute limb ischemia. The acquisition also expands Stryker’s worldwide presence, where Inari had already begun to gain traction.
Stryker Corporation (NYSE:SYK) anticipates organic sales growth of 8% to 9% in 2025, with adjusted EPS ranging from $13.45 to $13.70 per share, highlighting its market strength. Because of its sustained growth, astute acquisitions, and margin stability, the company makes it to Ken Fisher’s stock Portfolio.
9. AbbVie Inc. (NYSE:ABBV)
Upside Potential: 24.48%
Number of Hedge Fund Holders: 85
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical firm, based in North Chicago, Illinois. Since its inception in 2012, AbbVie has focused on discovering novel treatments to treat serious health diseases. The organization works in several therapeutic areas, including immunology, cancer, neuroscience, eye care, virology, and aesthetics. AbbVie is well recognized for its major therapies, including Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta. It also sells Botox for both therapeutic and cosmetic purposes, Vraylar for psychiatric issues, and a variety of treatments for migraines and eye diseases.
AbbVie Inc. (NYSE:ABBV) reported adjusted earnings per share of $2.16 per share and total net revenue of $15.1 billion in the fourth quarter of 2024, led by a 22% increase in its ex-Humira platform. Despite challenges from the Medicare Part D reform and foreign exchange implications, the company expects total net revenues of around $59 billion in 2025.
AbbVie Inc. (NYSE:ABBV) is continuing to build its pipeline through selective acquisitions and internal innovation. In 2024, the company purchased neuroscience specialist Cerevel Therapeutics, oncology-focused ImmunoGen, and Alzheimer’s therapeutic development Aliada for more than $20 billion. AbbVie anticipates incurring $248 million in milestone payments and R&D expenses in 2025 as a result of these acquisitions, causing its adjusted profit outlook to be revised.
In addition to strong financials, AbbVie Inc. (NYSE:ABBV) is developing multiple late-stage clinical initiatives in oncology, immunology, and neurology. Notably, the company is preparing for possible regulatory approvals of Teliso-V and Temab-A in lung and colorectal cancer, as well as further investigations of Emraclidine in psychiatric disorders and Tavapadon in Parkinson’s disease.
AbbVie Inc. (NYSE:ABBV) is a key holding in Ken Fisher’s stock portfolio, demonstrating its strong growth potential and diverse pipeline. With a strong product portfolio, active clinical development, and strategic acquisitions, it is well-positioned to maintain momentum and create long-term value in the healthcare industry.
8. Eli Lilly and Company (NYSE:LLY)
Upside Potential: 24.73%
Number of Hedge Fund Holders: 115
Eli Lilly and Company (NYSE:LLY), founded in 1876 and based in Indianapolis, Indiana, is a global pharmaceutical industry leader. The company creates novel drugs for diabetes, obesity, oncology, immunology, and the brain. It promotes well-known treatments such as Mounjaro, Trulicity, Zepbound, Verzenio, and Jaypirca.
Eli Lilly and Company (NYSE:LLY) surpassed expectations in 2024, exceeding initial sales guidance by $4 billion and EPS estimates by $4 per share, even after accounting for IPR&D expenditures. This result was driven by significant momentum in the incretin market, where Mounjaro and Zepbound continued to grow their presence.
Looking ahead, the year 2025 is predicted to be significant. The Phase 3 ACHIEVE-1 trial, which is investigating Orforglipron in type 2 diabetes, is expected to report results in Q2. It recently stated that the oral medication resulted in an 8% weight loss over 40 weeks, outperforming Ozempic’s 6% in similar individuals, and decreased blood sugar by 1.3%. Despite being slightly lower than Ozempic’s 2.1% reduction, Orforglipron’s oral convenience may provide a competitive advantage in a market that is traditionally dominated by injectables. The company’s share price increased by 16% upon the announcement of the results.
Furthermore, in Q3, Eli Lilly and Company (NYSE:LLY) anticipates critical results from the ATTAIN-1 and ATTAIN-2 obesity trials, which will support regulatory applications for Orforglipron in obesity by late 2025. Additional catalysts include SURPASS-CVOT data for tirzepatide in cardiovascular outcomes and preliminary results for Retatrutide from the TRIUMPH-4 study in overweight patients with osteoarthritis.
Eli Lilly and Company (NYSE:LLY) is also expanding its cancer pipeline through Jaypirca trials, which are aiming at earlier-stage medicines, and through neurodegenerative research. These accomplishments highlight the pharmaceutical company’s strong innovation engine, making it a strong pick in Ken Fisher’s stock portfolio.
7. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Upside Potential: 25.86%
Number of Hedge Fund Holders: 95
Intuitive Surgical, Inc. (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a pioneer in robotic-assisted surgery and a notable healthcare technology company in Ken Fisher’s stock portfolio. The da Vinci and Ion platforms are commonly utilized in minimally invasive procedures in urology, gynecology, thoracic, and colorectal surgery. Its ecosystem consists of the da Vinci 5 and Xi multiport systems, the SP single-port platform, and innovative equipment, such as SureForm staplers with SmartFire technology.
With 17% procedure growth and significant system installs in 2024, Intuitive Surgical, Inc. (NASDAQ:ISRG) exceeded expectations and produced strong financial results. Revenue for the full year increased by 17% to $8.4 billion, and the pro forma gross profit margin was 69%. The company predicts gross margins between 67% and 68% for 2025 and expects procedure growth to be between 13% and 16%. A 10% to 15% increase in operating expenses is anticipated, mostly as a result of facility investments, R&D, and legal costs. Currency headwinds, increased depreciation, and a larger mix of lower-margin products like da Vinci 5, Ion, and SP are all likely to have some minor impact on pro forma EPS.
The strategic decision to go direct in Italy, Spain, and Portugal with a base acquisition of $330 million, which is anticipated to close in the first half of 2026, is one of the major milestones. The da Vinci SP platform’s capabilities were further enhanced when the FDA approved the SP SureForm 45 stapler for use in thoracic, colorectal, and urologic operations.
Compared to laparoscopic and open surgery, da Vinci procedures considerably enhance clinical outcomes, according to a significant meta-analysis. Additionally, even among experienced surgeons, the da Vinci 5’s innovative force feedback technology showed less tissue injury.
Intuitive Surgical, Inc. (NASDAQ:ISRG) is still a well-known brand in robotic surgery and a significant holding in Ken Fisher’s stock portfolio, thanks to its sustained innovation, international growth, and sound financial standing.
6. Pfizer Inc. (NYSE:PFE)
Upside Potential: 37.43%
Number of Hedge Fund Holders: 92
Founded in 1849 and based in New York City, Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company with a diverse portfolio that includes rare illnesses, cancer, inflammation, and vaccines. The company’s RSV vaccine, ABRYSVO, is a major factor in its future growth as it keeps growing its presence in the adult and maternal vaccination markets.
Pfizer Inc. (NYSE:PFE) made $63.6 billion in 2024, thanks to robust sales of its non-COVID drugs, which saw an operational growth of 12%. The company paid out $9.5 billion in dividends to stockholders and recorded adjusted earnings per share of $3.11, up from $1.84 in 2023. In addition, Pfizer reduced its debt by $7.8 billion and made roughly $11 billion in internal research and development.
Looking ahead, Pfizer Inc. (NYSE:PFE) projects $61–$64 billion in revenue and $2.80–$3.00 in earnings per share for 2025. The company’s priorities include increasing R&D productivity, starting up to 13 pivotal trials, and advancing important medications, including sigvotatug vedotin (ADC), atirmociclib (a CDK4 inhibitor), and vaccinations like PCV-25 and C. diff. Furthermore, Pfizer is confident in its cost-saving plan, which aims to recover to pre-COVID operating margins and save $4.5 billion by the end of 2025, despite challenges from Medicare reforms under the IRA.
Adults aged 50–59 who are at a higher risk of developing severe RSV-associated lower respiratory tract disease (LRTD) should also receive the RSV vaccination, according to a vote made by the CDC’s Advisory Committee on Immunization Practices (ACIP) in April 2025. Among them is ABRYSVO, which the FDA authorized in October 2024 for use in high-risk people between the ages of 18 and 59. The change greatly expands the vaccine’s eligible population, subject to final approval. The European Commission recently amended the vaccine’s authorization to cover a larger adult population in March 2025, and it is currently approved in a number of overseas markets.
Thus, as Pfizer Inc. (NYSE:PFE) negotiates the post-COVID environment, ABRYSVO is becoming a key component of its vaccination approach. A restoration to revenue momentum is shown by the company’s wider RSV coverage, which also helps its competitive positioning.
Pfizer continues to be a carefully watched healthcare stock with promising long-term catalysts, thanks to significant institutional support, including a position in Ken Fisher’s stock portfolio.
5. Viatris Inc. (NASDAQ:VTRS)
Upside Potential: 38.71%
Number of Hedge Fund Holders: 48
With operations in more than 165 countries, Viatris Inc. (NASDAQ:VTRS) is a multifaceted international healthcare organization with its headquarters located in Canonsburg, Pennsylvania. In important therapeutic areas like cardiovascular, central nervous system, infectious diseases, and oncology, it provides a broad selection of prescription brands, generics, complicated generics, and biosimilars. The company has a robust worldwide distribution network that includes retail and institutional pharmacies, e-commerce platforms, and specialized channels, and it has a portfolio of well-known products like EpiPen, Lipitor, Celebrex, and Viagra.
Viatris Inc. (NASDAQ:VTRS) generated $14.7 billion in total revenue for the fiscal year ended December 31, 2024, which is a 2% increase on an operational basis adjusted for divestitures. Adjusted EPS was $2.65, and adjusted EBITDA was $4.7 billion. With costs associated with divestitures excluded, free cash flow was $2.6 billion. Viatris achieved its long-term gross leverage goal of 2.9x by retiring $3.7 billion in debt and returning about $825 million to shareholders.
The company anticipates a $500 million short-term sales hit in 2025 as a result of remediation work at its Indore factory, which includes a $385 million EBITDA headwind. Strong momentum is still present in emerging markets as well as core markets like China and Europe. As a result of more than 150 anticipated worldwide product launches, including sophisticated injectables like Octreotide and Iron Sucrose, Viatris Inc. (NASDAQ:VTRS) anticipates $450–$550 million in new product sales.
With six readouts anticipated this year and ten distinct Phase 3 compounds, the R&D pipeline is still strong. Selatogrel, cenerimod, and sotagliflozin—three important novel assets—are making steady progress. Supported by a robust anticipated free cash flow of $2 billion, the company anticipates over $1 billion in capital returns in 2025 through dividends and share repurchases.
Viatris Inc. (NASDAQ:VTRS) continues to be a key holding in Ken Fisher’s stock portfolio due to its capital discipline, operational execution, and developing pipeline, indicating long-term investor confidence in its approach.
4. UnitedHealth Group Incorporated (NYSE:UNH)
Upside Potential: 45.83%
Number of Hedge Fund Holders: 150
UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx are the four main business sectors of UnitedHealth Group Incorporated (NYSE:UNH), which is headquartered in Eden Prairie, Minnesota. The company offers a wide range of pharmaceutical care services, healthcare services, data analytics, and health benefit plans, both domestically and abroad.
Due to unforeseen difficulties in its Medicare Advantage (MA) businesses, UnitedHealth Group Incorporated (NYSE:UNH) updated its full-year adjusted EPS outlook to $26–$26.50 per share in the first quarter of 2025, which concluded on March 31. UnitedHealthcare’s MA margins suffered as care activity increased twice as quickly as first predicted, particularly in physician and outpatient services. A more complicated patient mix and lower-than-expected reimbursement for new patients from insurance, leaving specific areas, caused Optum Health to face a revenue shortfall at the same time. Although implementing the new CMS risk adjustment model has been challenging, the company is making efforts to enhance clinician involvement and streamline processes for more precise evaluations.
Notwithstanding these obstacles, UnitedHealth Group Incorporated (NYSE:UNH) maintained its $450–$455 billion consolidated revenue forecast for 2025, bolstered by better-than-expected results from Optum Rx and UnitedHealthcare. With a 3% rise in scripts as a result of new customer acquisitions and excellent retention, Optum Rx’s sales increased 14% year over year to surpass $35 billion.
In 2025, Optum Health anticipates adding 650,000 more patients to value-based care models, and UnitedHealth Group Incorporated (NYSE:UNH) is on track to serve an additional 800,000 Medicare Advantage members. Strong momentum in the Medicaid and commercial areas, supported by expanded services and state partnerships, was also recognized by the firm.
UnitedHealth Group Incorporated (NYSE:UNH) is committed to reaching its long-term EPS growth goal of 13%–16%, with a focus on digital engagement, operational efficiency, and technology-driven care delivery. Both income and growth-oriented investors should continue to keep an eye on UnitedHealth Group, which holds a significant position in Ken Fisher’s stock portfolio, valued at $1.7 billion.
3. Danaher Corporation (NYSE:DHR)
Upside Potential: 47.94%
Number of Hedge Fund Holders: 101
With its Biotechnology, Life Sciences, and Diagnostics divisions, Danaher Corporation (NYSE:DHR) is a multinational scientific and technology company. It offers cutting-edge instruments, supplies, and solutions for use in clinical diagnostics, research applications, and pharmaceutical development. Underpinned by its steady financial performance and innovation-driven growth, Danaher continues to be a prominent company in Ken Fisher’s stock portfolio, with a strong presence in the United States, China, and beyond.
Danaher Corporation (NYSE:DHR) recorded $23.9 billion in total sales for the fiscal year that concluded on December 31, 2024, a 1.5% decrease in core revenue. However, with free cash flow of $5.3 billion, or 135% of net income, the company achieved over 100% free cash flow conversion for the 33rd year in a row.
Across all segments, Danaher Corporation (NYSE:DHR) kept up its investment in innovation. The Cytiva Sefia platform in biotechnology is making it possible to produce CAR-Ts more effectively. Furthermore, Leica Microsystems, a subsidiary of DHR, enhanced its spatial biology imaging capabilities, and Beckman Coulter, also a subsidiary, introduced automated technologies to speed up cell line production in the life sciences. Danaher’s capacity to provide state-of-the-art clinical solutions is demonstrated in the diagnostics industry by Beckman’s new assays for Alzheimer’s research and Cepheid’s expansion in non-respiratory and women’s health diagnostics. Also, its position in precision diagnostics is strengthened by the FDA’s designation of its Alzheimer’s diagnostic test as a breakthrough device.
Despite a 2% foreign exchange loss, Danaher Corporation (NYSE:DHR) projects a 28.5% adjusted operating profit and a 3% increase in core sales in 2025. The company’s sustained emphasis on shareholder returns is evidenced by the 18.5% increase in its quarterly dividend to $0.32 per share. Thus, Danaher has a robust innovation engine, a global presence, and effective capital allocation, which position it for long-term, steady growth.
2. Merck & Co., Inc. (NYSE:MRK)
Upside Potential: 48.91%
Number of Hedge Fund Holders: 91
With hallmark medications in oncology, vaccines, and infectious illnesses, Merck & Co., Inc. (NYSE:MRK) is a leading worldwide healthcare company that works in both human and animal health. The company, which is well-known for its innovation-driven pipeline, keeps making significant R&D investments while negotiating the shifting dynamics of the worldwide market.
Merck & Co., Inc. (NYSE:MRK) generated $15.6 billion in total Q4 sales, which was 7% higher than the previous year (9% ex-FX). Sales of Keytruda increased 21% to $7.8 billion due to robust worldwide demand for both metastatic and early-stage malignancies. Additionally, the company’s Animal Health division reported strong 13% growth. Sales of GARDASIL, however, fell 18% as a result of shipments to China being halted due to high inventory levels at distribution partner Zhifei. Merck, however, is still optimistic about GARDASIL’s long-term prospects worldwide.
The company’s core business development is anticipated to counteract GARDASIL’s challenges in China, with revenue projections for 2025 ranging from $64.1 to $65.6 billion and non-GAAP EPS of $8.88 to $9.03. In addition to increasing its dividend, Merck & Co., Inc. (NYSE:MRK) increased its authorization for share repurchases to $12 billion, bolstering shareholder returns. Notably, the pipeline contains more than 20 potential blockbusters, such as WINREVAIR for pulmonary arterial hypertension, which has been approved in more than 35 countries and saw initial sales of $200 million.
Following promising Phase III findings in TGCT patients, Merck & Co., Inc. (NYSE:MRK) exercised its global commercialization rights for pimicotinib, a CSF-1R inhibitor created by Abbisko Therapeutics, on March 31, 2025, expanding its oncology pipeline. Merck’s long-term growth prospects are improved by this $85 million acquisition, which expands its extensive oncology bench.
Thus, Merck & Co., Inc. (NYSE:MRK) continues to be a high-conviction pharmaceutical investment in Ken Fisher’s stock portfolio because of its innovation-led approach, diversified portfolio, and dedication to capital discipline.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Upside Potential: 51.94%
Number of Hedge Fund Holders: 100
Thermo Fisher Scientific Inc. (NYSE:TMO) is a world leader in the provision of laboratory products, analytical tools, diagnostics, and scientific solutions in the life sciences. With operations across North America, Europe, Asia-Pacific, and beyond, the company provides cutting-edge tools and services to serve industrial, healthcare, and research applications.
The company reported $42.9 billion in revenue and adjusted EPS of $21.86 per share for the year. Results for the fourth quarter revealed an 8% increase in adjusted EPS to $6.10 and a 5% increase in revenue to $11.4 billion. With margins increasing to 23.9%, adjusted operating income increased by 7% to $2.72 billion. Thermo Fisher Scientific Inc. (NYSE:TMO) produced growth in electron microscopy, diagnostics, and pharmaceutical services throughout the end markets. Disciplined capital allocation, which included $4 billion in share buybacks, helped the company’s full-year free cash flow reach $7.3 billion.
Highlights of the segment-wise performance included Analytical Instruments’ 8% organic growth, which was fueled by increasing demand for mass spectrometry and electron microscopy. On the other hand, Specialty Diagnostics and Laboratory Products demonstrated sustained progress, bolstered by advancements in clinical research and transplant diagnostics, while Life Sciences Solutions increased its margin to 36.4%. Looking ahead, the company anticipates 3% to 4% organic growth and adjusted EPS between $23.10 and $23.50 in 2025, supported by productivity increases and the tried-and-true PPI Business System.
The Krios 5 Cryo-TEM, a next-generation imaging platform with improved optics and AI-enabled automation, was recently introduced by Thermo Fisher Scientific Inc. (NYSE:TMO). With up to 25% more throughput than previous models, it makes atomic-level structural biology discoveries possible. Additionally, the system has sustainable design components that assist environmental and energy efficiency objectives. For investors following Ken Fisher’s stock portfolio, in which Thermo Fisher continues to be a strategic investment, this innovation demonstrates the company’s dedication to furthering scientific discovery.
Overall, Thermo Fisher Scientific Inc. (NYSE:TMO) ranks first among Billionaire Ken Fisher’s 10 Finance Stock Picks with Huge Upside Potential. While we acknowledge the potential of these companies, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TMO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
